6 Method Documentation

The handling of BLQ data for concentration data presentation in TLFs and for the NCA are documented in BLQ data handling. Section NCA models provides an overview on the profiles types handled by IQnca for NCA. Details of the underlying methodology to derive the terminal slope as well as the AUC are discussed in Terminal slope calculation and AUC calculation methods. A complete overview on the implemented PK parameters and on when they are calculated is given in Overview of NCA parameters.

6.1 Grouping and profile differentiation

The analysis data is annotated with a GROUP and a PROFILE name that are used for annotation and stratification. Data of one individual can contain multiple PK concentration profiles. For example, for a cross over study studying food effects in which single dose profiles are measured in part A and part B the profile names could be: “Part A - single dose fasted”, “Part B - single dose fed”. Each subject furthermore belongs to a group which is used for annotation and further stratification. Typically, the treatment, e.g., “200 mg o.d.”, would be used for the group.

The group and the profile names are used throughout the analysis. Individual data listings and figures with individual data per panel are annotated with group name and profile. Summary tables and plots are always generated per profile, but may also be stratified by the group.

6.2 NCA models

Depending on the profile type and the type of administration, different NCA models are applied. The NCA model decides which parameters are derived during the analysis. Currently, IQnca supports the following profile types and administration types for the analysis of blood and plasma samples:

Table 6.1: **NCA models**
Type Category	Option
Profile Type	Single Dose
	First Dose
	Steady State^a
Administration Type	IV Bolus^b
	IV Infusion
	Extravascular^a
^a Unique pre-dose sample required.
^b Pre-dose sample is substituted by extrapolation

In case multiple profiles are provided for a subject, IQnca splits the data internally per unique profile and administration type and applies the corresponding NCA model.

6.3 Pre-dose data handling

Pre-dose samples are identified by negative times or the time being equal to zero. They are kept in the data set as is and reported and presented unchanged in the listings of individual concentration data or plots of individual data.

Positive pre-dose concentrations above the LLOQ are flagged for first or single dose profiles of exogenous compounds and handled as missing in summary tables and NCA.

The NCA requires a concentration at dosing time (i.e., C0) for a complete AUC calculation. C0 is defined as the pre-dose observation in the data set for infusion and extravascular administration. In case of bolus administration a pre-dose concentration is required to have time zero such that it is defined as C0. Imputation of C0 is needed if the pre-dose sample is missing or in case of bolus administration has a negative time. Imputation rules are summarized in Table 6.2 and the description of C0.

Note that the imputed values of C0 are not considered for determining Tmax/Cmax or Tmin/Cmin and that only one pre-dose sample per profile is allowed.

Table 6.2: **Missing pre-dose imputation for AUC calculation**
	Exogenous compound		Endogenous compound
Administration	Single/First Dose	Steady State	Single/First Dose	Steady State
Bolus^a	back-extrapolated^b	back-extrapolated^b	back-extrapolated^b	back-extrapolated^b
Infusion or extravascular	0	minimum observed concentration over dosing interval	minimum observed concentration	minimum observed concentration over dosing interval
Note:
Only one pre-dose sample allowed per profile. Imputed values are not considered for Tmax/Cmax and Tmin/Cmin calculation.
^a Imputation of missing as well as pre-dose samples with negative time.
^b Log-linear regression of first two data points. Or, if one of the values is negative or the second concentration is smallerthan the first, the first non zero concentration is imputed

6.4 BLQ data handling

Concentration records that are below the LLOQ, called BLQ data, are flagged in the dataset by checking whether the actually recorded concentration value is below the LLOQ. Data that are actually below the limit of detection are not handled separately, but are pooled with the BLQ data. BLQ data need special handling for the data presentation and summary in listings, tables and figures as well as the NCA.

6.4.1 For Listings

In listings of individual data, concentrations below the LLOQ are displayed as “BLQ” or “BLLOQ (<\(lloq\))” with \(lloq\) being the numerical value of the LLOQ.

6.4.2 For Summary Tables and NCA

The alternative BLQ handling methods that can be used for summary tables and NCA are described in Table 6.3. BLQ observations are handled differently for the cases shown in Table 6.4 that also indicates their default setting in IQnca.

Table 6.3: **BLQ handling methods**
Method	Description
asis	Keep value as reported in original data
zero	Impute zero value
LLOQ/2	Impute LLOQ/2 value
LLOQ	Impute LLOQ value
missing	Handle as missing (do not use for calculations)

Table 6.4: **Conditions for which BLQ methods are defined separately**
Condition	Default BLQ handling method
BLQ observation before the first observations above the LLOQ	0
BLQ observation in between observations that are above the LLOQ	missing
BLQ observation the first observation after the last observation above the LLOQ^*	LLOQ/2
BLQ observation following the first observation after the last observation above the LLOQ	missing
Note:
When determining the condition for each observation, ignored records are not considered. These are observations with missing time or concentration values and can include manually selected records.
^* Requires following BLQ observations. A single BLQ observation at the end of the profile will be handled as observation in between observations above the LLOQ.

Note that the same settings are used for summary tables and NCA. If zero imputation is used the corresponding concentrations are used for arithmetic mean and standard deviation (SD), but not for the geometric summary statistics.

6.4.3 For Individual and Summary Plots

Per default, the settings applied for NCA and summary tables are adopted when plotting individual or summary PK concentrations.

Alternatively, the applied BLQ handling method is only conditioned on whether the y-(concentration) axis that is used in a particular plot is linear or log transformed. That is, one of the BLQ handling methods listed in Table 6.3 is applied to all BLQ observations when plotting on linear scale. Another or the same is used for all BLQ observations when plotting on log transformed scale. Summaries, e.g., arithmetic or geometric means, are calculated considering these settings meaning that a summary value displayed in a plot may not be the same as listed in a table if different BLQ settings are used.

6.5 Terminal slope calculation

The terminal slope is determined by least-squares of a regression line to log-transformed terminal concentration data points. The PK parameter \(\lambda_z\) is defined as the negative of the regression slope which is determined analytically with \(t_i\) and \(\bar{t}\), the times and corresponding mean, as well as \(cl_i\) and \(\bar{cl}\), the log-transformed concentration and corresponding mean.

\[ \lambda_z = - \text{slope} = - \frac{\sum_{i=1}^{N} (t_i-\bar{t}) (cl_i-\bar{cl})}{\sum_{i=1}^{N} (t_i-\bar{t})^2} \]

The goodness of the fit is described by the coefficient of determination, R², and its adjusted version.

\[ R^2 = -\lambda_z \cdot \frac{\sum_{i=1}^{N} (t_i-\bar{t}) (cl_i-\bar{cl})}{\sum_{i=1}^{N} (cl_i-\bar{cl})^2} \]

\[ R^2_{adjusted} = 1 - (1 - R^2) \frac{n - 1}{n - 2} \]

The selection of terminal data points to be used for slope calculation can be done automatically or manually. The “BestSlope” algorithm which is implemented in IQnca and is used per default is described in the following section.

6.5.1 Automatic terminal slope selection

The algorithm considers all observations from the maximum value to the last nonzero observation. The slope and corresponding adjusted R² is determined for the last three, the last four, etc. and all observations under consideration.

The finally selected data points are defined as the highest number of terminal points that achieve an adjusted R² within a defined tolerance compared to the largest adjusted R² achieved over all tested sets of data points. The slope is not determined if only two or fewer data points are available or if all concentration values are identical.

6.6 AUC calculation methods

The AUC calculation is based on the trapezoidal method using either the linear trapezoidal rule or the logarithmic trapezoidal rule. That is, for each AUC segment between two consecutive observations, \(c_1\) and \(c_2\), the AUC is determined as the product of either the arithmetic or the logarithmic mean of the concentration and the time interval (\(t_2 - t_1\)). Equations for the AUC per observation interval based on the linear of logarithmic rule are given in AUC interval calculus. All segment AUCs are then added to give the total AUC for the considered time range (e.g., over the dosing interval, the observed time range, or a user-defined time interval).

The AUC calculation for the considered time range may require the imputation of concentrations if no observation is available for the start or end time points. For example, no trough measurement was taken and the AUC over a dosing interval for a steady-state dose is calculated, or if the user requires to determine the AUC for a time span with a start or end time not included in the observation times. Imputed concentrations are determined via linear or logarithmic interpolation before the last observed time point or by extrapolation after the observed time point. Note that concentrations before the first observed time point are interpolated between C0 and the first observed time point. Extrapolation is based on the terminal slope (cf. section on slope calculation) of logtransformed values.

Of note, the extrapolation of the AUC to infinity is a special case of extrapolation of a concentration to a time point after the last observation and is handled analogue. The calculus of the interpolated and extrapolated concentrations as well as for the AUC extrapolated to infinity are described in Concentration interpolation/extrapolation.

IQnca provides four different options consisting of combinations of linear or logarithmic AUC calculation and linear or logarithmic concentration interpolation, which can be selected by the parameter AUCMETHD in the function IQdataNCA. Table 6.5 indicates in which cases the linear or logarithmic version of each method is used.

Extrapolation of AUC to infinity is based on the last nonzero concentration and the terminal slope on log-scale.

Table 6.5: **AUC calculation options**
Option	Trapezoidal rule for AUC of interval^*	Interpolation of concentration^†
Linear Log	linear before Tmax, logarithmic after Tmax	linear before Tmax, logarithmic after Tmax^‡
LinearUp LogDown	linear if c₂ > c₁, logarithmic if c₂ < c₁	linear if c₂ > c₁, logarithmic if c₂ < c₁
Linear LinearInterpolation	linear	linear
Linear LinearLogInterpolation	linear	linear before Tmax, logarithmic after Tmax^‡
Note:
Concentrations are extrapolated using the terminal slope on logarithmic scale.
^* In case that at least for one of the endpoints of an interval the concentration is zero or negative or the concentrations at the endpoints are the same, the linear trapezoidal rule is used.
^† If a to-be-interpolated point lies in an interval where at least one of the endpoint concentration is zero or negative, linear interpolation is used.
^‡ In case of BOLUS administration where C0 > CMAX, logarithmic interpolation and logarithmic trapezoidal rule determining AUC is also used for points inbetween C0 and CMAX

Notes on exceptions from the general rule settings for AUC calculation for a segment

Linear trapezoidal rule is always used if any of the concentrations defining a segment is negative or zero or the concentrations are equal. In these cases, the logarithmic mean is not defined,
In case of BOLUS administration and if the extrapolated value of C0 is larger than CMAX, the logarithmic trapezoidal rule determining the AUC is used for the whole profile.

Notes on whether linear or logarithmic interpolation/extrapolation is used

Extrapolation to later timepoints is always performed on logarithmic scale using the terminal slope that was estimated for the respective profile,
Extrapolation to earlier timepoints is performed on linear scale,
Linear interpolation is always used if the to-be-interpolated concentration lies in an interval where at least one endpoint concentration is zero or negative or the endpoint concentrations are equal.
In case of BOLUS administration where C0 > CMAX and logarithmic interpolation is chosen for observations after Tmax, logarithmic interpolation is also used for points between C0 and CMAX
Extrapolation cannot be performed and the corresponding AUC cannot be determined if no calculated slope is available.

6.6.1 AUC interval calculus

The AUC and the area under the first moment curve (AUMC) for an interval between two consecutive observations based on the linear trapezoidal rule is calculated as follows.

\[ \left. AUC \right|_{t_1}^{t_2} = \frac{c_1 + c_2}{2} \cdot \left( t_2 - t_1 \right) \]

\[ \left. AUMC \right|_{t_1}^{t_2} = \frac{t_1 \cdot c_1 + t_2 \cdot c_2}{2} \cdot \left( t_2 - t_1 \right) \]

Using the logarithmic mean instead of the arithmetic mean, the AUC and AUMC are calculated according to the following equations.

\[ \left. AUC \right|_{t_1}^{t_2} = \frac{c_2 - c_1}{\ln(\frac{c_2}{c_1})} \cdot \left( t_2 - t_1 \right) \]

\[ \left. AUMC \right|_{t_1}^{t_2} = \frac{t_2 \cdot c_2 - t_1 \cdot c_1}{\ln(\frac{c_2}{c_1})} \cdot \left( t_2 - t_1 \right) - \frac{c_2 -c_1}{\ln(\frac{c_2}{c_1})²}\cdot \left( t_2 - t_1 \right)² \]

6.6.2 Concentration interpolation/extrapolation

Interpolated concentrations \(\hat{c}\) are calculated as follows via linear interpolation of two consecutive observations either using the original values (\(\hat{c}_{\text{lin}}\)) or logarithms of the concentration values (\(\hat{c}_{\text{log}}\)).

\[ \hat{c}_{\text{lin}} = c_1 + \left| \frac{\hat{t}-t_1}{t_2 - t_1} \right| \left( c_2 - c_1 \right) \]

\[ \hat{c}_{\text{log}} = \exp \left( \ln(c_1) + \left| \frac{\hat{t}-t_1}{t_2 - t_1} \right| \left( \ln(c_2) - \ln(c_1) \right) \right) \]

Extrapolated concentrations \(\tilde{c}\) are determined via the terminal slope \(\lambda_Z\) from the last observed value \(c_{last}\). The last observed value is the last value that is not missing or below the limit of quantification (BLQ).

\[ \tilde{c} = c_{last} \cdot \exp \left(-\lambda_Z \cdot (\tilde{t} - t_{last}) \right) \]

For the special case of \(\tilde{t} \to \infty\), the extrapolation of the concentration results in an extrapolated AUC after the last observation according to

\[ AUC_{E} = \frac{c_{\text{last}}}{\lambda_Z} \]

6.7 Overview of NCA parameters

A large number of NCA parameters is provided per individual and as summary tables by IQnca. Depending on the route of administration and type of profile of the considered data, the created output differs and is automatically adjusted by IQnca. The following tables provide an overview over all NCA parameters included in IQnca.

Parameters are divided into three tables depending on the type of profile data:

Parameters derived for all types of profiles (Table 6.6)
Additional parameters derived only for single/first dose profiles (Table 6.7)
Additional parameters derived only for steady-state dosing (Table 6.8)

Further the tables are subdivided by the admissible administration profiles BOLUS, INFUSION and EXTRAVASCULAR.

For the formulas used to calculate the parameters see Table 6.9.

6.7.1 Last observation defintion

The parameter TLST is defined as the last timepoint at which the concentration is greater than the lower limit of quantification. This is the default behavior. An alternative definition is setting TLST as the last timepoint where the concentration is non-zero. The latter can be achieved by setting the parameter CTLASTwinnonlinbehavior as “TRUE” in the function nca_IQdataNCA. Note that this alternative definition includes possible values which are imputed as “LLOQ” or “LLOQ/2” as non-zero concentration values.

6.7.2 For all profile types

Table 6.6: **Parameters derived for all types of profiles.**
PKPARAMCD	Name	Description	Unit^a
ALL ADMINISTRATION TYPES
LAMZICPT	Intercept of regression	Intercept of the log-linear regression for finding LAMZ.	–
CORRXY	Correlation Between TimeX and Log ConcY	Correlation between time and logarithmic concentration due to the log-linear regression for LAMZ.	–
LAMZ	Lambda z	First order rate constant associated with the terminal portion of the curve. The negative of the slope obtained from a log-linear regression involving datapoints in the terminal part of the curve. For the exact calculation see section 6.5.	1/TIMEUNIT
LAMZNPT	Number of Points for Lambda z	Number of points involved in the regression for LAMZ calculation.	–
LAMZLL	Lambda z Lower Limit	Smallest time point (Lower Limit) of the data involved in the regression for LAMZ calculation.	TIMEUNIT
LAMZUL	Lambda z Upper Limit	Largest time point (Upper Limit) of the data involved in the regression for LAMZ calculation.	TIMEUNIT
R2	R Squared	Coefficient of determination due to the regression for LAMZ calculation.	–
R2ADJ	R Squared Adjusted	Adjusted coefficient of determination due to the regression for LAMZ calculation.	–
LAMZHL	Half-Life Lambda z	Terminal half-life.	TIMEUNIT
SPAN	Span	Relative range of HL determination	–
TMAX	Time of CMAX	Time of maximal concentration. If profile type is SS then only regarding concentrations in the dosing interval TAU.	TIMEUNIT
CMAX	Max Conc	Maximal concentration, occurring at TMAX. If not unique, then the first maximum is used. If profile type SS, then maximal concentration inside the dosing interval TAU.	CONCUNIT
CMAXD	Max Conc Norm by Dose	Dose normalised CMAX.	CONCUNIT/DOSEUNIT
TMIN	Time of CMIN Observation	Time of minimal concentration. If profile type is SS then only regarding concentrations in the dosing interval TAU.	TIMEUNIT
CMIN	Min Conc	Minimal concentration, occurring at TMIN. If not unique, then the first minimum is used. If profile type SS, then minimal concentration inside the dosing interval TAU.	CONCUNIT
CMIND	Min Conc Norm by Dose	Dose normalised CMIN.	CONCUNIT/DOSEUNIT
TLST	Time of Last Nonzero Conc	Time of last quantifiable observation. If BLLOQ handling rule is set to use LLOQ/2 or LLOQ for the first BLLOQ value post last observable, then Clast and Tlast will be set based on this first BLLOQ imputation. This is counterintuitive - but in order to be aligned with Winnonlin we had to add this exception.	TIMEUNIT
CLST	Last Nonzero Conc	Concentration at Tlast. If BLLOQ handling rule is set to use LLOQ/2 or LLOQ for the first BLLOQ value post last observable, then Clast and Tlast will be set based on this first BLLOQ imputation. This is counterintuitive - but in order to be aligned with Winnonlin we had to add this exception.	CONCUNIT
CLSTP	Last Nonzero Conc Pred	Predicted concentration value at TLST by regression of terminal phase.	CONCUNIT
AUCALL	AUC All	Area under the curve from the time of dosing to the time of the last observation (quantifiable or unquantifiable). Equal to AUCLST if the last observation is quantifiable. Otherwise, AUCALL will not be equal to AUCLST as it includes the additional area from the last quantifiable concentration up to the last observation made.	CONCUNIT*TIMEUNIT
AUCIFO	AUC Infinity Obs	Area under the curve from dosing time to infinity, extrapolated from the observed last quantifiable concentration CLST.	CONCUNIT*TIMEUNIT
AUCIFOD	AUC Infinity Obs Norm by Dose	Dose normalised AUCIFO, using the last given dose if doses of differing quantities are given.	CONCUNIT*TIMEUNIT/DOSEUNIT
AUCIFP	AUC Infinity Pred	Area under the curve from dosing time to infinity, extrapolated from the predicted last quantifiable concentration CLSTP.	CONCUNIT*TIMEUNIT
AUCIFPD	AUC Infinity Pred Norm by Dose	Dose normalised AUCIFP.	CONCUNIT*TIMEUNIT/DOSEUNIT
AUCLST	AUC to Last Nonzero Conc	Area under the curve from the time of dosing to the time of the last quantifiable observation TLST.	CONCUNIT*TIMEUNIT
AUCLSTD	AUC to Last Nonzero Conc Norm by Dose	Dose normalised AUCLST.	CONCUNIT*TIMEUNIT/DOSEUNIT
AUCPEO	AUC %Extrapolation Obs	Percentage of AUCIFO due to extrapolation from TLST to infinity.	%
AUCPEP	AUC %Extrapolation Pred	Percentage of AUCIFP due to extrapolation from TLST to infinity.	%
AUMCIFO	AUMC Infinity Obs	Area under the first moment curve from dosing time to infinity, extrapolated from the observed last quantifiable concentration CLST.	CONCUNIT*TIMEUNIT^2
AUMCIFP	AUMC Infinity Pred	Area under the first moment curve from dosing time to infinity, extrapolated from the predicted last quantifiable concentration CLSTP.	CONCUNIT*TIMEUNIT^2
AUMCLST	AUMC to Last Nonzero Conc	Area under the first moment curve from the time of dosing to the time of the last quantifiable observation TLST.	CONCUNIT*TIMEUNIT^2
AUMCPEO	AUMC % Extrapolation Obs	Percentage of AUMCIFO due to extrapolation from TLST to infinity.	%
AUMCPEP	AUMC % Extrapolation Pred	Percentage of AUMCIFP due to extrapolation from TLST to infinity.	%
AUCINTX	Interval AUC [t1;t2 TIMEUNIT]	Interval AUC. Using defined AUC calculation and interpolation method. X=1,…,n.	CONCUNIT*TIMEUNIT
AUCINTXD	Interval AUC [t1;t2UNIT] Norm by Dose	Dose normalized Interval AUC. Using defined AUC calculation and interpolation method. X=1,…,n.	CONCUNIT*TIMEUNIT/DOSEUNIT
EXTRAVASCULAR
TLAG	Time Until First Nonzero Conc	Time of the observation prior the first quantifiable observation. Equal to zero for BOLUS or INFUSION administration.	TIMEUNIT
MRTEVIFO	MRT Extravasc Infinity Obs	Mean residence time from dosing time to infinity, extrapolated using CLST.	TIMEUNIT
MRTEVIFP	MRT Extravasc Infinity Pred	Mean residence time from dosing time to infinity, extrapolated using CLSTP.	TIMEUNIT
MRTEVLST	MRT Extravasc to Last Nonzero Conc	Mean residence time from dosing time to TLST.	TIMEUNIT
BOLUS
C0	Initial Conc	Concentration at dosing time. Note that the parameter is only listed in case of BOLUS administration. If there is no concentration at time zero available, then C0 is calculated by the following rules: For INFUSION and EXTRAVASCULAR administration: If there is a concentration with negative time point (pre-dose), that time is set to zero and the respective concentration becomes C0. Else if there are only positive time points: SINGLE DOSE and FIRST DOSE data: for exogenous compounds set C0 to zero, for endogenous compounds set C0 to the minimum observed. STEADY STATE data: set C0 to the minimum observed in the dosing interval TAU. For BOLUS: If there is no concentration value at time zero, then C0 is always extrapolated as follows: Find C0 by performing backwards extrapolation by log-linear regression of the first two concentrations C1 and C2. In case of C1 < C2, or C1 or C2 non-positive, set C0 equal to the first positive concentration after time zero instead. C1 and C2 are the first two consecutive concentrations after time zero, after removal of outliers.	CONCUNIT
AUCPBEO	AUC %Back Extrapolation Obs	Percentage of AUCIFO due to back extrapolation of C0 if the first measured concentration is not at dosing time.	%
AUCPBEP	AUC %Back Extrapolation Pred	Percentage of AUCIFP due to back extrapolation of C0 if the first measured concentration is not at dosing time.	%
BOLUS/INFUSION
MRTIVIFO	MRT Intravasc Infinity Obs	Mean residence time from dosing time to infinity, based on AUCIFO, in case of BOLUS and INFUSION administration.	TIMEUNIT
MRTIVIFP	MRT Intravasc Infinity Pred	Mean residence time from dosing time to infinity, based on AUCIFP, in case of BOLUS and INFUSION administration.	TIMEUNIT
MRTIVLST	MRT Intravasc to Last Nonzero Conc	Mean residence time from dosing time to TLST.	TIMEUNIT
^a TIMEUNIT and DOSEUNIT are taken from the dataset and kept as is. The CONCUNIT from the dataset is rescaled to mass per L.

6.7.3 Only for single and first dose profiles

Table 6.7: **Additional parameters derived for single/first dose profiles.**
PKPARAMCD	Name	Description	Unit^a
BOLUS/INFUSION
CLO	Total CL Obs	Total body clearance based on CLST.	CLROUTINE
CLP	Total CL Pred	Total body clearance based on CLSTP	CLROUTINE
VSSO	Vol Dist Steady State Obs	Estimated volume of distribution at steady state, based on last observed concentration CLST.	VOLROUTINE
VSSP	Vol Dist Steady State Pred	Estimated volume of distribution at steady state, based on last predicted concentration CLSTP.	VOLROUTINE
VZO	Vz Obs	Volume of distribution associated with the terminal phase, based on CLST.	VOLROUTINE
VZP	Vz Pred	Volume of distribution associated with the terminal phase, based on CLSTP.	VOLROUTINE
EXTRAVASCULAR
CLFO	Total CL Obs by F	Total body clearance, divided by fraction of dose absorbed (bioavailability), based on CLST.	CLROUTINE
CLFP	Total CL Pred by F	Total body clearance, divided by fraction of dose absorbed (bioavailability), based on CLSTP.	CLROUTINE
VZFO	Vz Obs by F	Volume of distribution associated with the terminal phase, divided by fraction of dose absorbed (bioavailability), based on CLST.	VOLROUTINE
VZFP	Vz Pred by F	Volume of distribution associated with the terminal phase, divided by fraction of dose absorbed (bioavailability), based on CLSTP.	VOLROUTINE
^a TIMEUNIT and DOSEUNIT are taken from the dataset and kept as is. The CONCUNIT from the dataset is rescaled to mass per L.

6.7.4 Only for steady-state profiles

Table 6.8: **Additional parameters derived for steady-state profiles.**
PKPARAMCD	Name	Description	Unit^a
ALL ADMINISTRATION TYPES
SWING	Swing	For profile type SS only. The degree of fluctuation over one dosing interval at steady state (CMIN).	–
SWINGTAU	Swing_Tau	For profile type SS only. The degree of fluctuation over one dosing interval at steady state (CTAU).	–
AUMCTAU	AUMC Over Dosing Interval	Area under the first moment curve for the interval from dosing time to dosing time + TAU.	CONCUNIT*TIMEUNIT^2
AUCPTAUE	AUC %Extrapolation Over Dosing Interval	Percentage of AUC due to extrapolation in steady state.	%
BOLUS/INFUSION
CLSS	Total CL for Dose Int	Total body clearance at steady state.	CLROUTINE
VZSS	Vz for Dose Int at SS	Volume of distribution associated with the terminal phase, calculated with AUCTAU.	VOLROUTINE
EXTRAVASCULAR
CLFSS	Total CL by F for Dose Int	Total body clearance at steady state divided by the fraction of dose absorbed (bioavailability).	CLROUTINE
VZFSS	Vz for Dose Int at SS by F	Volume of distribution associated with the terminal phase, divided by fraction of dose absorbed (bioavailability), calculated with AUCTAU.	VOLROUTINE
^a TIMEUNIT and DOSEUNIT are taken from the dataset and kept as is. The CONCUNIT from the dataset is rescaled to mass per L.

6.7.5 Formulas

The following table contains the formulas for the parameters.

Table 6.9: **Relevant formulas of the parameters.**
PKPARAMCD	Formulas	Units^a
LAMZ	\(\lambda_z\), see section 6.5	1/TIMEUNIT
LAMZHL	\(\frac{ln(2)}{LAMZ}\)	TIMEUNIT
SPAN	\(\frac{LAMZUL-LAMZLL}{LAMZHL}\)	–
CMAXD	\(\frac{CMAX}{DOSE}\)	CONCUNIT/DOSEUNIT
CMIND	\(\frac{CMIN}{DOSE}\)	CONCUNIT/DOSEUNIT
CLSTP	\(\exp(b0-\lambda_z \cdot TLST)\)	CONCUNIT
CAVG	\(\frac{AUCTAU}{TAU}\)	CONCUNIT
FLUCP	\(\frac{CMAX-CMIN}{CAVG}\cdot 100\)	%
FLUCPTAU	\(\frac{CMAX-CTAU}{CAVG}\cdot 100\)	%
AILAMZ	\(\frac{1}{1-\exp(-\lambda_z\cdot TAU)}\)	–
SWING	\(\frac{CMAX-CMIN}{CMIN}\)	–
SWINGTAU	\(\frac{CMAX-CTAU}{CTAU}\)	–
AUCALL	\(AUC\)	CONCUNIT*TIMEUNIT
AUCIFO	\(AUCLST + \frac{CLST}{\lambda_z}\)	CONCUNIT*TIMEUNIT
AUCIFOD	\(\frac{AUCIFO}{DOSE}\)	CONCUNIT*TIMEUNIT/DOSEUNIT
AUCIFP	\(AUCLST + \frac{CLSTP}{\lambda_z}\)	CONCUNIT*TIMEUNIT
AUCIFPD	\(\frac{AUCIFP}{DOSE}\)	CONCUNIT*TIMEUNIT/DOSEUNIT
AUCLST	\(AUC \rvert_{T_0}^{TLST}\)	CONCUNIT*TIMEUNIT
AUCLSTD	\(\frac{AUCLST}{DOSE}\)	CONCUNIT*TIMEUNIT/DOSEUNIT
AUCPBEO	\(\frac{ AUC \rvert_{T_0}^{T_1}}{AUCIFO}\cdot 100\)	%
AUCPBEP	\(\frac{ AUC \rvert_{T_0}^{T_1}}{AUCIFP}\cdot 100\)	%
AUCPEO	\((1 - \frac{AUCLST}{AUCIFO}) \cdot 100\)	%
AUCPEP	\((1 - \frac{AUCLST}{AUCIFP}) \cdot 100\)	%
AUCTAU	\(AUC \rvert_{T_0}^{TAU}\)	CONCUNIT*TIMEUNIT
AUCTAUD	\(\frac{AUCTAU}{DOSE}\)	CONCUNIT*TIMEUNIT/DOSEUNIT
CLFO	\(\frac{DOSE}{AUCIFO}\)	CLROUTINE
CLFP	\(\frac{DOSE}{AUCIFP}\)	CLROUTINE
CLFSS	\(\frac{DOSE}{AUCTAU}\)	CLROUTINE
CLO	\(\frac{DOSE}{AUCIFO}\)	CLROUTINE
CLP	\(\frac{DOSE}{AUCIFP}\)	CLROUTINE
CLSS	\(\frac{DOSE}{AUCTAU}\)	CLROUTINE
VSSO	\(MRTIVIFO\cdot CLO\)	VOLROUTINE
VSSP	\(MRTIVIFP\cdot CLP\)	VOLROUTINE
VZFO	\(\frac{DOSE}{AUCIFO\cdot \lambda_z}\)	VOLROUTINE
VZFP	\(\frac{DOSE}{AUCIFP\cdot \lambda_z}\)	VOLROUTINE
VZFSS	\(\frac{DOSE}{AUCTAU\cdot \lambda_z}\)	VOLROUTINE
VZO	\(\frac{DOSE}{AUCIFO\cdot \lambda_z}\)	VOLROUTINE
VZP	\(\frac{DOSE}{AUCIFP\cdot \lambda_z}\)	VOLROUTINE
VZSS	\(\frac{DOSE}{AUCTAU\cdot \lambda_z}\)	VOLROUTINE
AUMCIFO	\(AUMCLST + \frac{CLST \cdot TLST}{\lambda_z} + \frac{CLST}{\lambda_z^2}\)	CONCUNIT*TIMEUNIT^2
AUMCIFP	\(AUMCLST + \frac{CLSTP \cdot TLST}{\lambda_z} + \frac{CLSTP}{\lambda_z^2}\)	CONCUNIT*TIMEUNIT^2
AUMCLST	\(AUMC \rvert_{T_0}^{TLST}\)	CONCUNIT*TIMEUNIT^2
AUMCPEO	\((1 - \frac{AUMCLST}{AUMCIFO}) \cdot 100\)	%
AUMCPEP	\((1 - \frac{AUMCLST}{AUMCIFP}) \cdot 100\)	%
AUMCTAU	\(AUMC \rvert_{T_0}^{TAU}\)	CONCUNIT*TIMEUNIT^2
AUCPTAUE	\(\frac{AUCTAU-AUCLST}{AUCTAU}\cdot 100\) if TAU > TLST \(0\) else	%
MRTEVIFO	SD,FD: \(\frac{AUMCIFO}{AUCIFO}\) SS: \(\frac{AUMCTAU + \tau\cdot (AUCIFO - AUCTAU)}{AUCTAU}\)	TIMEUNIT
MRTEVIFP	SD,FD: \(\frac{AUMCIFP}{AUCIFP}\) SS: \(\frac{AUMCTAU + \tau\cdot (AUCIFP - AUCTAU)}{AUCTAU}\)	TIMEUNIT
MRTEVLST	\(\frac{AUMCLST}{AUCLST}\)	TIMEUNIT
MRTIVIFO	SD,FD: INFUSION: \(\frac{AUMCIFO}{AUCIFO} - \frac{DUR}{2}\) BOLUS: \(\frac{AUMCIFO}{AUCIFO}\) SS: INFUSION: \(\frac{AUMCTAU + \tau\cdot (AUCIFO - AUCTAU)}{AUCTAU} - \frac{DUR}{2}\) BOLUS: \(\frac{AUMCTAU + \tau\cdot (AUCIFO - AUCTAU)}{AUCTAU}\)	TIMEUNIT
MRTIVIFP	SD,FD: INFUSION: \(\frac{AUMCIFP}{AUCIFP} - \frac{DUR}{2}\) BOLUS: \(\frac{AUMCIFP}{AUCIFP}\) SS: INFUSION: \(\frac{AUMCTAU + \tau\cdot (AUCIFP - AUCTAU)}{AUCTAU} - \frac{DUR}{2}\) BOLUS: \(\frac{AUMCTAU + \tau\cdot (AUCIFP - AUCTAU)}{AUCTAU}\)	TIMEUNIT
MRTIVLST	INFUSION: \(\frac{AUMCLST}{AUCLST}-\frac{DUR}{2}\) BOLUS: \(\frac{AUMCLST}{AUCLST}\)	TIMEUNIT
^a TIMEUNIT and DOSEUNIT are taken from the dataset and kept as is. The CONCUNIT from the dataset is rescaled to mass per L.